GLP-1 Weight Loss in Lexington, KY: Below Kentucky's Obesity Rate, Still Behind on Price Transparency

Kentucky Medicaid covers GLP-1s for diabetes only

Kentucky Medicaid's pharmacy benefit runs through a single contracted PBM, MedImpact. Its Preferred Drug List and Prior Authorization Criteria (version dated August 2026) require an ICD-10 Type 2 diabetes diagnosis plus A1c lab documentation (6.5% or higher, or a historical equivalent) for every covered GLP-1 receptor agonist, Mounjaro, Ozempic (pen and tablet), Trulicity, Victoza, Rybelsus, exenatide, liraglutide, Soliqua, and Xultophy ¹²¹³.

Each drug's criteria entry ends with the same line: "Drugs used for anorexia, weight loss, or weight gain are excluded from coverage." Wegovy, Zepbound, and Saxenda, the three GLP-1s actually indicated for obesity, do not appear anywhere in the 34-page PDL or the 289-page PA criteria document ¹²¹³. Kentucky Medicaid, in other words, covers GLP-1s for diagnosed type 2 diabetes only; there is no state-Medicaid pathway to these drugs for weight loss alone.

What GLP-1 care costs in Lexington today

Of three Lexington providers checked, exactly one posts a number. Medi-Weightloss at 2909 Richmond Road, Suite 40 publishes GLP-1 pricing on its Lexington clinic page: compounded semaglutide at $99 for the first month and compounded tirzepatide at $199 for the first month, both stepping up to a $199/month membership after that, plus a separate $199 one-time new-patient visit fee, on 1-, 3-, or 6-month plans. Brand-name Wegovy and Zepbound are offered where insurance covers them. Checked 2026-08-28 ⁹.

Rewind Medical, at 4384 Clearwater Way, Suite 190, runs GLP-1-assisted weight loss under its "Be Thin" program and publishes no price anywhere: the homepage, the dedicated weight-loss page, and the specials page all route to a phone call or a booked consultation instead of a number ¹⁰. Lexington Clinic, the city's largest multi-specialty physician group, lists a general Endocrinology service page with no weight-management or GLP-1 program at all, and no mention of semaglutide, tirzepatide, Wegovy, Ozempic, Zepbound, or Mounjaro ¹¹.

Astra's national price is $68/month for semaglutide and $118/month for tirzepatide on 12-month plans, $816 and $1,416 billed annually. That is the same everywhere Astra operates; it is not a Lexington rate.

UK HealthCare carries the region, and Fayette isn't the underserved part

Fayette County carries no active, county-wide primary care HPSA designation. A broad "Low Income - North Central Lexington" geographic designation existed in HRSA's records but was withdrawn on 08/25/1980 and never reinstated. The current designations are all facility-specific: Health First Bluegrass FQHC (score 22, designation population 74,197), Bluegrass Primary Health Care Center FQHC (score 21, population 82,200), the University of Kentucky FQHC (score 21, population 45,688), and the federal prison FMC-Lexington (score 12, population 1,466) ⁸. Lexington as a whole is not classified as medically underserved for primary care; the shortage sits in specific safety-net clinics serving low-income and incarcerated populations.

Lexington's specialist backbone is UK HealthCare, the University of Kentucky's academic medical center, which serves as the referral hub for a much larger, higher-need catchment across rural and Appalachian central and eastern Kentucky, a region with far more HPSA-designated counties than Fayette itself. No public dataset quantifies endocrinologist or obesity-medicine-specialist counts, appointment wait times, or referral patterns specific to Lexington, so that piece of the access picture is a genuine data gap rather than a number to guess at ⁸.

What is measurable locally is price transparency, and only one of three checked providers passes. Telehealth answers both problems at once: a licensed prescriber without the referral queue, at a price published before the visit. See the Kentucky GLP-1 overview for statewide context.